NuCana applies novel ProTide technology to transform some of the most widely prescribed chemotherapeutic agents, nucleoside analogues, into more effective and safer medicines for cancer patients. NuCana’s lead product, Acelarin, a novel ProTide form of gemcitabine, is in a pivotal Phase III trial for patients with biliary tract cancer. The company has additional novel ProTide molecules in clinical studies; NUC-3373 for colorectal cancer and NUC-7738 for haematological and other solid malignancies. The treatments under development are targeted to improve the success rates of these already validated chemotherapies whilst significantly reducing the challenging side effect profile of such medications. NuCana is listed on Nasdaq with ticker: NCNA

LocationEdinburgh, UK
CEOHugh Griffith
Partner Bali Muralidhar
Websitewww.nucana.com